XML 20 R8.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Cash flows from operating activities:    
Net income (loss) $ 24,335 $ (158,965)
Adjustments to reconcile net income (loss) to net cash provided by operations:    
Loss on divestitures 0 195,729
Depreciation and amortization 18,235 21,804
Stock-based compensation expense 4,137 4,119
Provision for deferred income taxes 9,362 (22,290)
Credit loss expense 19 998
Gain on sale of assets (2,203) (2,412)
Gain on insurance recovery 0 (874)
Amortization of original issue discount and debt issuance costs 394 885
Change in assets and liabilities:    
Increase in receivables (2,462) (13,734)
Decrease in inventories 5,007 9,481
Increase in other assets (3,711) (1,027)
Increase in accounts payable 1,466 12,498
Increase (decrease) in accrued liabilities and other 405 (3,916)
Net cash provided by operating activities 54,984 42,296
Cash flows from investing activities:    
Capital expenditures (34,419) (29,940)
Proceeds from divestitures, net of cash disposed 14,485 48,499
Proceeds from sale of property, plant and equipment 3,819 3,188
Proceeds from insurance property claim 0 1,385
Other investing activities 3,089 0
Net cash provided by (used in) investing activities (13,026) 23,132
Cash flows from financing activities:    
Borrowings on lines of credit 0 177,541
Payments on lines of credit 0 (224,292)
Debt issuance costs (811) (50)
Purchases of treasury stock (22,695) (4,504)
Proceeds from employee stock plans 1,497 17
Other financing activities (2,639) (9,538)
Net cash used in financing activities (24,648) (60,826)
Effect of exchange rate changes on cash 91 (119)
Net increase in cash, cash equivalents, and restricted cash 17,401 4,483
Cash, cash equivalents, and restricted cash at beginning of period 18,237 38,901
Cash, cash equivalents, and restricted cash at end of period $ 35,638 $ 43,384